DACH1: its role as a classifier of long term good prognosis in luminal breast cancer.
<h4>Background</h4>Oestrogen receptor (ER) positive (luminal) tumours account for the largest proportion of females with breast cancer. Theirs is a heterogeneous disease presenting clinical challenges in managing their treatment. Three main biological luminal groups have been identified...
Saved in:
Main Authors: | Desmond G Powe, Gopal Krishna R Dhondalay, Christophe Lemetre, Tony Allen, Hany O Habashy, Ian O Ellis, Robert Rees, Graham R Ball |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2014
|
Subjects: | |
Online Access: | https://doaj.org/article/65a8a8ef87a7433b922d346ad74caebd |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Pseudokinase TRIB3 Negatively Regulates the HER2 Receptor Pathway and Is a Biomarker of Good Prognosis in Luminal Breast Cancer
by: Alba Orea-Soufi, et al.
Published: (2021) -
Communitybuilding über Discord – der DACH-Bibliothekswesen-Server
by: Victoria Geske, et al.
Published: (2021) -
DACH1 suppresses breast cancer as a negative regulator of CD44
by: Hanxiao Xu, et al.
Published: (2017) -
Silencing DACH1 promotes esophageal cancer growth by inhibiting TGF-β signaling.
by: Liang Wu, et al.
Published: (2014) -
A ferroptosis-associated gene signature for the prediction of prognosis and therapeutic response in luminal-type breast carcinoma
by: Yang Peng, et al.
Published: (2021)